Category: Lexicon

Lexicon Pharmaceuticals (NASDAQ: NASDAQ:) reported in their second quarter 2024 earnings call a modest growth in their INPEFA business and a net loss of $53.4 million. The company highlighted the resubmission of their New Drug Application (NDA) for Zynquista, the advancement of their Phase 3 study for Sotagliflozin in hypertrophic…